Literature DB >> 29557488

[Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy].

F Gebauer1, A I Damanakis2, C Bruns2.   

Abstract

BACKGROUND: Several case series reported results of surgical resection in patients with pancreatic ductal adenocarcinoma in a metastasized stage. AIM: A summarized overview of the current state of knowledge and a summary of the results of currently available studies.
MATERIAL AND METHODS: A systematic search was carried out in MEDLINE and PubMed with respect to metastasized pancreatic cancer and surgical resection.
RESULTS: The evidence level for surgical resection in the metastasized stage is weak and so far no prospective trials are available. The largest single-arm trial included 85 patients with hepatic metastasis. In cases of hepatic oligometastasis an overall survival of 11-14 months was observed. In the presence of pulmonary metastasis, overall survival seems to be prolonged compared to intra-abdominal metastasis, although the evidence level is relatively weak.
CONCLUSION: According to the available results, a general recommendation for surgical resection in a metastasized stage cannot be given; however, the results show a possible benefit for some well-selected patient subgroups. Prospective trials must validate these data and investigate the use of combined surgical and systemic treatments in the case of resectable metastatic pancreatic cancer.

Entities:  

Keywords:  Ablative procedures; Hepatic metastasis; Multimodal therapy; Pulmonary metastases; Resection

Mesh:

Year:  2018        PMID: 29557488     DOI: 10.1007/s00104-018-0626-1

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  31 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy.

Authors:  Yong-Qiang Hua; Peng Wang; Xiao-Yan Zhu; Ye-Hua Shen; Kun Wang; Wei-Dong Shi; Jun-Hua Lin; Zhi-Qiang Meng; Zhen Chen; Hao Chen
Journal:  Pancreatology       Date:  2017-09-01       Impact factor: 3.996

3.  Radical surgery of oligometastatic pancreatic cancer.

Authors:  T Hackert; W Niesen; U Hinz; C Tjaden; O Strobel; A Ulrich; C W Michalski; M W Büchler
Journal:  Eur J Surg Oncol       Date:  2016-11-09       Impact factor: 4.424

4.  Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis.

Authors:  J Klempnauer; G J Ridder; H Bektas; R Pichlmayr
Journal:  Oncology       Date:  1996 Jan-Feb       Impact factor: 2.935

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?

Authors:  Isabella Frigerio; Paolo Regi; Alessandro Giardino; Filippo Scopelliti; Roberto Girelli; Claudio Bassi; Stefano Gobbo; Paolo Tinazzi Martini; Paola Capelli; Mirko D'Onofrio; Giuseppe Malleo; Laura Maggino; Elena Viviani; Giovanni Butturini
Journal:  Ann Surg Oncol       Date:  2017-05-17       Impact factor: 5.344

Review 7.  Resection of primary pancreatic cancer and liver metastasis: a systematic review.

Authors:  Christoph W Michalski; Mert Erkan; Norbert Hüser; Michael W Müller; Mark Hartel; Helmut Friess; Jörg Kleeff
Journal:  Dig Surg       Date:  2009-02-12       Impact factor: 2.588

8.  Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer.

Authors:  Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Marlies Michl; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Maximilian Niyazi; Falk Roeder; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  Pancreatology       Date:  2016-03-30       Impact factor: 3.996

9.  Metastatic patterns of cancers: results from a large autopsy study.

Authors:  Guy Disibio; Samuel W French
Journal:  Arch Pathol Lab Med       Date:  2008-06       Impact factor: 5.534

10.  Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.

Authors:  Michael Tachezy; Florian Gebauer; Monika Janot; Waldemar Uhl; Alessandro Zerbi; Marco Montorsi; Julie Perinel; Mustapha Adham; Christos Dervenis; Christos Agalianos; Giuseppe Malleo; Laura Maggino; Alexander Stein; Jakob R Izbicki; Maximilian Bockhorn
Journal:  Surgery       Date:  2016-04-03       Impact factor: 3.982

View more
  2 in total

1.  Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).

Authors:  Miaoyan Wei; Si Shi; Jie Hua; Jin Xu; Xianjun Yu
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

Review 2.  Systemic Therapy for Metastatic Pancreatic Cancer.

Authors:  Thomas J Ettrich; Thomas Seufferlein
Journal:  Curr Treat Options Oncol       Date:  2021-10-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.